TY  - CHAP
M1  - Book, Section
TI  - Chlamydia and Other Sexually Transmitted Infections
A1  - Lavoie, Suzanne R.
A2  - Boulton, Matthew L.
A2  - Wallace, Robert B.
Y1  - 2022
N1  - 
T2  - Maxcy-Rosenau-Last Public Health & Preventive Medicine, 16e
AB  - Three  hundred  and  seventy-six  million  new  cases  of  the  four  curable  (chlamydia,  gonorrhea,  syphilis,  and  trichomoniasis)  sexually  transmitted  infections  (STIs)  are  estimated  to  occur  each  year,  according  to  the  World  Health  Organization  (WHO).1  This  amounts  to  more  than  1  million  curable  STIs  occurring  each  day.  The  burden  of  viral  STIs  is  similarly  high,  with  an  estimated  417  million  prevalent  cases  of  herpes  simples  virus  infection  (HSV)  and  approximately  291  million  women  infected  with  human  papillomavirus  (HPV).1  In  contrast  to  these  infections,  many  countries  have  achieved  successful  control  of  other  STIs  like  chancroid  (etiologic  agent  Haemophilus  ducreyi)  and  lymphogranuloma  venereum  or  LGV  (etiologic  agent  Chlamydia  trachomatis  serovars  L1,  L2,  and  L3).1  In  2016,  WHO  released  the  “Global  health  sector  strategy  on  sexually  transmitted  infections  2016-2021,”  with  a  goal  of  ending  STI  epidemics  as  a  major  public  health  concern.2  This  strategy  outlined  several  guiding  principles  including:  achieving  universal  health  coverage;  use  of  evidence-based  interventions  and  policies;  promoting  human  rights,  gender  equality,  and  health  equality;  working  through  partnerships;  integration  across  relevant  sectors;  and  engagement  and  empowerment  of  people  most  affected.  With  this  in  mind,  several  goals  to  be  achieved  by  2030  include:  ≤50  cases  of  congenital  syphilis  per  100,000  live  births  in  80%  of  countries;  90%  reduction  in  T.  pallidum  incidence  globally;  90%  reduction  in  N.  gonorrhoeae  incidence  globally;  and  90%  national  vaccination  coverage  and  at  least  80%  district  coverage  in  countries  with  HPV  vaccine  in  their  national  immunization  program.2  
SN  - 
PB  - McGraw Hill
CY  - New York, NY
Y2  - 2024/04/18
UR  - accessmedicine.mhmedical.com/content.aspx?aid=1182665840
ER  -